These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 25732268)

  • 21. Colectomy rate in acute severe ulcerative colitis in the infliximab era.
    Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R
    Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study.
    Christensen KR; Steenholdt C; Brynskov J
    Scand J Gastroenterol; 2015 Aug; 50(8):1018-24. PubMed ID: 25861832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up.
    Kohn A; Daperno M; Armuzzi A; Cappello M; Biancone L; Orlando A; Viscido A; Annese V; Riegler G; Meucci G; Marrollo M; Sostegni R; Gasbarrini A; Peralta S; Prantera C
    Aliment Pharmacol Ther; 2007 Sep; 26(5):747-56. PubMed ID: 17697208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis.
    Olsen T; Rismo R; Gundersen MD; Paulssen EJ; Johnsen K; Kvamme JM; Goll R; Florholmen J
    Cytokine; 2016 Mar; 79():90-5. PubMed ID: 26775117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm.
    Johnsen KM; Goll R; Hansen V; Olsen T; Rismo R; Heitmann R; Gundersen MD; Kvamme JM; Paulssen EJ; Kileng H; Johnsen K; Florholmen J
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):98-104. PubMed ID: 27749779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis.
    De Vos M; Dewit O; D'Haens G; Baert F; Fontaine F; Vermeire S; Franchimont D; Moreels T; Staessen D; Terriere L; Vander Cruyssen B; Louis E;
    J Crohns Colitis; 2012 Jun; 6(5):557-62. PubMed ID: 22398050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date.
    Thukral C; Cheifetz A; Peppercorn MA
    Drugs; 2006; 66(16):2059-65. PubMed ID: 17112300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
    Lawrance IC; Radford-Smith GL; Bampton PA; Andrews JM; Tan PK; Croft A; Gearry RB; Florin TH
    J Gastroenterol Hepatol; 2010 Nov; 25(11):1732-8. PubMed ID: 21039834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab.
    Hassan C; Ierardi E; Burattini O; De Francesco V; Zullo A; Stoppino G; Panella C; Morini S
    Dig Liver Dis; 2007 Sep; 39(9):811-7. PubMed ID: 17652038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort.
    Hiroz P; Vavricka SR; Fournier N; Safroneeva E; Pittet V; Rogler G; Schoepfer AM;
    Scand J Gastroenterol; 2014 Oct; 49(10):1207-18. PubMed ID: 25120029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.
    Papamichael K; Rivals-Lerebours O; Billiet T; Vande Casteele N; Gils A; Ferrante M; Van Assche G; Rutgeerts PJ; Mantzaris GJ; Peyrin-Biroulet L; Vermeire S
    J Crohns Colitis; 2016 Sep; 10(9):1015-23. PubMed ID: 27022161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.
    Zhou Z; Dai C; Liu WX
    Hepatogastroenterology; 2015; 62(138):309-18. PubMed ID: 25916055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis.
    Lv R; Qiao W; Wu Z; Wang Y; Dai S; Liu Q; Zheng X
    PLoS One; 2014; 9(1):e86692. PubMed ID: 24475168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral tacrolimus as maintenance therapy for refractory ulcerative colitis--an analysis of outcomes in two London tertiary centres.
    Landy J; Wahed M; Peake ST; Hussein M; Ng SC; Lindsay JO; Hart AL
    J Crohns Colitis; 2013 Dec; 7(11):e516-21. PubMed ID: 23623737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.
    Taxonera C; Rodríguez C; Bertoletti F; Menchén L; Arribas J; Sierra M; Arias L; Martínez-Montiel P; Juan A; Iglesias E; Algaba A; Manceñido N; Rivero M; Barreiro-de Acosta M; López-Serrano P; Argüelles-Arias F; Gutierrez A; Busquets D; Gisbert JP; Olivares D; Calvo M; Alba C;
    Inflamm Bowel Dis; 2017 Aug; 23(8):1394-1402. PubMed ID: 28671873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conflict of interest: real and perceived--a more mature consideration is needed.
    Andrews JM; Costello SP; Agarwal AK; Bampton P; Beswick L; Connor S; Ghaly S; O'Connor S; Pudipeddi A; Sechi A; Sparrow M; Walsh AJ
    Intern Med J; 2016 Mar; 46(3):377-9. PubMed ID: 26968604
    [No Abstract]   [Full Text] [Related]  

  • 37. Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis.
    Volonaki E; Mutalib M; Kiparissi F; Shah N; Lindley KJ; Elawad M
    Eur J Gastroenterol Hepatol; 2015 Dec; 27(12):1425-8. PubMed ID: 26426835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study.
    Festa S; Scribano ML; Pugliese D; Bezzio C; Principi M; Ribaldone DG; Allocca M; Mocci G; Bodini G; Spagnuolo R; Vernia P; Mazzuoli S; Costa F; Barberio B; Cosintino R; Zerboni G; Aratari A; Armuzzi A; Papi C
    United European Gastroenterol J; 2021 May; 9(4):507-516. PubMed ID: 33259773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study.
    Reich KM; Chang HJ; Rezaie A; Wang H; Goodman KJ; Kaplan GG; Svenson LW; Lees G; Fedorak RN; Kroeker KI
    Aliment Pharmacol Ther; 2014 Sep; 40(6):629-38. PubMed ID: 25039715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Anti-TNF-alpha therapy in ulcerative colitis].
    Lakatos PL; Lakatos L
    Orv Hetil; 2008 May; 149(20):921-7. PubMed ID: 18467261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.